SCHEMBL574632

SCHEMBL574632

CC(C)C(C)NCC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
PTGS2 P35354 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ECE1 P42892 2/20 0.42
MME P08473 1/20 0.36
ACE P12821 1/20 0.36
CPA1 P15085 1/20 0.36
ACE2 Q9BYF1 1/20 0.36
CTH P32929 1/20 0.36
EGLN1 Q9GZT9 2/20 0.34
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
LDHA P00338 1/20 0.33
SRR Q9GZT4 1/20 0.33
GABRP O00591 2/20 0.32
GABRD O14764 2/20 0.32
GABRA1 P14867 2/20 0.32
GABRB1 P18505 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14930533 1.00 ALDH1A1 (0.43) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL7717660 0.79 ALDH1A1 (0.43) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL22305848 0.79 ALDH1A1 (0.38) ALDH1A1TDP1
SCHEMBL27796756 0.78 ALDH1A1 (0.39) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL161143 0.78
SCHEMBL23483772 0.77
SCHEMBL9803026 0.77 SLC7A5 (0.46) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL16267760 0.76
SCHEMBL203810 0.76
SCHEMBL25407138 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024130161-A2 NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF BIONECURE THERAPEUTICS INC (US) 2024-06-20 WO disclosed
US-20230292741-A1 NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES X-THERMA, INC. (US) 2023-09-21 US disclosed
US-11564388-B2 Supercooling methods for preservation of biological samples X-THERMA, INC. (US) 2023-01-31 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-4013440-A1 THERAPEUTIC PEPTIDES Cohbar Inc. (US) 2022-06-22 EP disclosed
EP-3997231-A1 METHODS FOR MAKING RECOMBINANT PROTEIN Monash University (AU) 2022-05-18 EP disclosed
US-20210061755-A1 AROMATIC VINYL OR AROMATIC ETHYL DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) 2021-03-04 US disclosed
WO-2021030792-A1 THERAPEUTIC PEPTIDES COHBAR, INC. (US) 2021-02-18 WO disclosed
WO-2021030752-A1 THERAPEUTIC PEPTIDES COHBAR, INC. (US) 2021-02-18 WO disclosed
WO-2021030469-A1 THERAPEUTIC MITOCHONDRIAL PEPTIDES COHBAR, INC. (US) 2021-02-18 WO disclosed
WO-2013114363-A2 ANTIMICROBIAL AGENTS YEDA RESEARCH AND DEVELOPMENT CO.LTD. (IL) 2013-08-08 WO disclosed
EP-2600885-A2 METHODS OF TREATING AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS) AND NEURODEGENERATIVE DISEASES Ramot at Tel Aviv University, Ltd. (IL) 2013-06-12 EP disclosed
WO-2013059885-A2 POLYPEPTIDE CONSTRUCTS AND USES THEREOF CEPHALON AUSTRALIA PTY LTD (AU) 2013-05-02 WO disclosed
WO-2013030840-A2 ADHESIVE BIOPOLYMERS AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2013-03-07 WO disclosed
EP-2478009-A1 PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS Ramot at Tel-Aviv University Ltd. (IL) 2012-07-25 EP disclosed
WO-2012017439-A2 METHODS OF TREATING AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS) AND NEURODEGENERATIVE DISEASES RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2012-02-09 WO disclosed
WO-2011033506-A9 ISOLATED PON1 POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF IN TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2011-05-05 WO disclosed
WO-2011033511-A1 PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2011-03-24 WO disclosed
EP-1756272-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH AMYLOID FIBRIL FORMATION YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2007-02-28 EP disclosed
WO-2005066337-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH AMYLOID FIBRIL FORMATION YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11564388-B2 Supercooling methods for preservation of biological samples PPIG, AQP3, PYGB ALDH1A1 4840/4885LMNA 157/4885MAPT 1057/4885
US-20210061755-A1 AROMATIC VINYL OR AROMATIC ETHYL DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION PDCD1, CD274, PDCD1LG2 ALDH1A1 69/4885LMNA 2222/4885MAPT 2465/4885
US-20230292741-A1 NOVEL SUPERCOOLING METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES PPIG, AQP3, AQP1 ALDH1A1 4823/4885LMNA 195/4885MAPT 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.